Search

OBJECTIVE: Fibromyalgia (FM) is a clinical syndrome characterized by prominent physical and psychological impairment and widespread pain on both sides of the body, above and below the waist, and along the axial skeleton. It often causes sleep difficulties, memory impairment, mood changes, irritable bowel syndrome, and fatigue. Our study aimed to investigate the relationship between FM and prolidase (peptidase D) and histone H3 protein levels by comparing a patient group with a healthy control group. PATIENTS AND METHODS: In total, 176 people were examined in our study, 88 of whom were healthy and 88 of whom had FM. Serum level was measured by ELISA. Then the results were analyzed using SPSS. All p < 0.05 were considered statistically significant. RESULTS: A significant increase in the levels of prolidase was observed in the patient group compared with the control group (6.28-4.68, p

Background: Breast cancer is a leading cause of death in women worldwide. Genetic polymorphisms have been reported to be important etiological factors. Murine double minute 2 (MDM2) T309G interacts with p53 and mutations in p53 are present in approximately 50% of all cancers. However, it has been reported that effect of the polymorphism on breast cancer risk may vary in different populations. Here, we therefore investigated whether there is an association between MDM2 T309G (rs2279744) polymorphism and breast cancer in a Turkish population. Materials and Methods: We analysed 110 patients with breast cancer and 138 matched? controls. For genotyping, polymerase chain reaction and restriction length fragment polymorphism methods were used. Results: A significant difference was observed between case and control groups with regard to the distribution of the MDM2 T309G polymorphism (p

WOS: 000388616700013, PubMed ID: 25926273, This study was aimed at determining the acute and chronic toxic effects of cypermethrin, propetamphos, and combined cypermethrin and propetamphos. Four groups, each comprising 10 animals, were established for the acute (a) and chronic (b) toxicity trials, and in total, 80 male Wistar albino rats were used. In the acute toxicity trial, the first group was maintained for control purposes, and groups 2a, 3a, and 4a were administered only once with 80 mg/kg.bw of cypermethrin, 25 mg/kg.bw of propetamphos and 80 mg/kg.bw of cypermethrin combined with 25 mg/kg.bw of propetamphos, respectively, by gavage directly into the stomach. In the chronic toxicity trial, the first group was also maintained for control purposes, while groups 2b, 3b, and 4b were administered daily with 12 mg/kg.bw of cypermethrin, 4 mg/kg.bw of propetamphos, and 12 mg/kg.bw of cypermethrin combined with 4 mg/kg.bw of propetamphos respectively, by gavage directly into the stomach for 60 days. Blood and tissue (liver, kidney, brain, spleen, and testis) samples were taken 24 h after pesticide administration in the acute toxicity trial and at the end of day 60 in the chronic toxicity trial. Oxidative stress (MDA, NO, SOD, CAT, GSH-Px, and G6PD) parameters, serum biochemical parameters (glucose, triglyceride, cholesterol, HDL, LDL, BUN, creatinine, AST, ALT, ALP, protein, and albumin) and hepatic drug-metabolizing parameters (CYP2E1, CYPB5, CYTC, GST, and GSH) were investigated in the samples. When administered either alone or in combination, both pesticides inhibited the antioxidant enzymes and increased MDA and NO levels. For the drug-metabolizing parameters investigated, particularly in the chronic period, either increase (CYP2E1, CYPB5, and CYTC) or decrease (GST and GSH) was observed. Furthermore, some negative changes were detected in the serum biochemical parameters. In result, cypermethrin and propetamphos combinations and long-term exposure to these combinations produced a greater toxic effect than the administration of these insecticides alone. (C) 2015 Wiley Periodicals, Inc., Erciyes University [TSA-091132], Contract grant sponsor: Research Fund of Erciyes University.; Contract grant number: TSA-091132.

Amaç: Akciğer kanseri dünya genelinde kansere bağlıölümlerin önde gelen nedenidir. Tanısal cihazlar ve teknolojik gelişmelerebağlı tedavi seçeneklerinde ilerlemeye rağmen, akciğer kanseri hastalarındagenel mortalite oranı hala yüksektir. Akciğer kanseri hastalarında sağkalımoranları, özellikle ilerlemiş inoperabl hastalıkta, immunoterapi gibi yenitedavi seçeneklerine rağmen düşüktür. p53, kanser hastalarının %60-70’inde mutasyonauğramaktadır ve bu nedenle son zamanlarda yapılan çalışmalar göstermektedir ki,serum anti-p53 antikorunun, over, özefagus, meme ve akciğer kanseri gibi bazıkanser türlerinin dedekte edilmesinde biyobelirteç olarak dikkate alınabilir.Bu çalışmada, akciğer kanseri hastalarında, serum anti-p53antikor düzeylerinintanısal ve prognostik önemini araştırmayı amaçladık.Yöntem: Çalışmayaakciğer kanseri (AK) tanısı nedeniyle evreleme için 18F-FDG-PET / BTgörüntüleme amacı ile bölümümüze sevk edilen hastalar, toraks BT’sinde şüphelipulmoner nodül olup, patolojik FDG birikimi göstermeyen hastalar (NAPN= Non-avid FDG gösterenpulmoner nodül) ve sağlıklı gönüllüler dahil edildi. Serum anti-p53antikordüzeyleri tüm hastalarda ELISA yöntemi ile ölçüldü. Hastaların ortalama takipsüresi 13 ay idi.Bulgular: Çalışmaya toplam 65 AK hastası (58E/7K), 47 NAPNhastası (20E/27K) ve 34 sağlıklı gönüllü (26E /8K) dahil edildi. Ortalama serumanti-p53antikor seviyeleri AK hastalarında 3.4ng/mL, NAPN hastalarında 3.77ng/mL, sağlıklı gönüllülerde 3.07 ng/ mL idi. AK hastaları ile NAPN hastaları arasındaserum anti-p53antikor düzeyi için istatistiksel olarak anlamlı fark yoktu (p =0.678). Hatta, hastalarve sağlıklı gönüllüler arasında serum anti-p53Ab düzeyi için istatistikselolarak anlamlı fark yoktu (p = 0.377). Hastaların iki yıllık medyan sağkalımı14 aydı. Hastalarınsağkalım hızında, serum anti-p53Ab düzeyinin > 3.4 ng/ mL veya ≤3.4 ng/ mL olmasının herhangi bir etkisininolmadığı bulundu (p = 0.652).Sonuç: Anti-p53antikoru,karsinogeneziste çok önemli olmasına rağmen, serum anti-p53antikor düzeyininakciğer kanseri tanısında ve sağkalım oranlarında tek başına önemli olmadığını düşünüyoruz. Karsinogenezistebirden fazla faktör vardır ve bu durumun nedeni olabilir. Akciğer kanserihastalarının teşhisi için serum anti-p53antikor düzeylerinin bilinen bir katofdeğeri yoktur. Bu nedenle, buantikorun tümör spesifikliği olmadığını ve serum anti-p53antikor düzeyininakciğer kanseri taraması için uygun olmadığını düşünüyoruz., Objective: Lung cancer is the leading causeof cancer-related deaths worldwide. Despite advancement in diagnostic tools andtreatment options with technological developments, overall mortality rates inlung cancer patients remains high. Survival rates in lung cancer patients islow especially in advanced diseased inoperable patients in spite of newtreatment options like immunotherapy. p53 is mutated in 60-70% of cancerpatients and for this reason has been extensively studied recent researches suggest that serumanti-p53Ab can be considered as biomarkers to detect many types of cancers; asovarian cancer, esophageal cancer, breast cancer and lung cancer. In this studywe aimed that are there any diagnostic and prognostic importance of serumanti-p53Ab levels in lung cancer patients.Method: Patients were included who werereferred to our department with the purpose of 18F-FDG-PET/CTimaging for staging due to lung cancer diagnosis (LC) and patients who wereperformed 18F-FDG-PET/CT for diagnosis in the cause of the suspectedpulmonary nodule in thorax CT but not detected pathologic FDG accumulation(NAPN=pulmonary nodule with non-avid-FDG) and healthy volunteers. Serumanti-p53Ab levels were measured with ELISA method in the all patients. Meanfollow up time of patients were 13 months.Results: A total of 65 LC patients(58M/7F), 47 patients with NAPN (20M/27F), and a total of 34 healthy volunteers(26M/8F) were included in this study. Median serum anti-p53Ab levels are3.4ng/mL in LC patients, 3.77ng/mL in NAPN patients, 3.07ng/mL in healthyvolunteers. There is no statistically significant difference for serumanti-p53Ab level between LC patients and NAPN patients (p=0.678). Moreover there is no statistically significant differencefor serum anti-p53Ab level between patients and healthy volunteers (p=0.377). Two-year median survival ofpatients was 14 month. It has been found that there is no effect of serumanti-p53Ab level whether >3.4 or ≤3.4 on the patient survival rate (p=0.652).Conclusions: Even thoughanti-p53Ab is very important in carcinogenesis, we think that serum anti-p53Ablevel by itself is not important in lung cancer diagnosis and survival rates.There are multiple factors in carcinogenesis and this may be the reason of thissituation. There is no known cut off value of serum anti-p53 Ab levels fordiagnosis of lung cancer patients. Therefore we think that this antibody is nottumor spesific and serum anti-p53 Ab level measurement is not appropriate forlung cancer screening.

WOS: 000454950700019, Objective: The study was aimed to evaluate the cytotoxic activity of acetone extract of leaves, flower and body of Euphorbia macroclada boiss on human breast cancer cell line (MCF-7). Material: The cells were plated at a cell density of 1x10(5) cells in 96-well plates and grown with DMEM medium containing supplemented with 10% FBS and 1% penicillin. The cells were treated by different concentrations of acetone extract of Euphorbia macroclada boiss (10-1000 mu g/mL) during 24, 48 and 72 h. The cytotoxic activities of the tested compounds were determined by cell proliferation analysis using standard (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Results: After the evaluation of cytotoxicity assay results, it is determined that flower and body parts have a significant cytotoxic effect on MCF-7 breast cancer cell line. The values that obtained reading at 570 nm spectrophotometrically, were analyzed with GraphPad Prism7 and IC50 growth inhibition values was determined. Conclusion: The results of MTT assay showed that leaves, flower and body significantly reduced % cell viability comparative to the control. It was also shown that body had more growth inhibitory effect on MCF-7 cell compared to the leaves part.

WOS: 000441784000038, PubMed ID: 29881964, In the current study, the possible prophylactic and therapeutic effects of colostrum (COL) on acute organ injury caused by paracetamol (PAR) in rats were evaluated. Within the scope of this study, a 2-month-old male (150-200 g) 70 Wistar Albino rat was used and a total of seven groups were designed. The first group (CNT) was maintained for control purposes. The second group (COL-1) was given COL for 1 day, at a dose of 500 mg/kg at 6-h intervals, and blood and tissue sampling was performed at 24 h. The third group (COL-7) received COL for 7 days, at a dose of 500 mg/kg at 6-h intervals on day 1 and at a daily dose of 500 mg/kg on the following days, and blood and tissue samples were taken at the end of seventh day. The fourth group (PAR-1) was administered with PAR at a dose of 1.0 g/kg bw and was blood and tissue sampled at 24 h. The fifth group (PAR-7) received PAR at a dose of 1.0 g/kg bw on day 1 and was blood and tissue was removed at the end of day 7. The sixth group (PAR+COL-1) was administered with a combination of PAR (1 g/kg bw) and COL (500 mg/kg at 6-h intervals), and blood and tissue samples were collected at 24 h. The seventh group (PAR+COL-7) received 1.0 g/kg bw of PAR on day 1 and was given COL throughout the 7-day study period (at a dose of 500 mg/kg at 6-h intervals on day 1 and at a daily dose of 500 mg/kg on the following days). In the seventh group, blood and tissue samples were taken at the end of seventh day. Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), glucose, creatinine, triglyceride, total bilirubin, total protein and albumin levels/activities were analysed in the serum samples. The malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) levels/activities, known as oxidative stress parameters, were assayed for tissue homogenates and blood (erythrocytes/plasma); in addition, enzyme activities of GSH S-transferase (GST), cytochrome P4502E1 (CYP2E1), NADH-cytochrome b5 reductase (CYTB5), glucose-6-phosphate dehydrogenase (G6PD), NADPH-cytochrome P450 C reductase (CYTC) and glutathione (GSH) levels/activities defined as drug metabolising parameters were measured in liver homogenates. In result, it was determined that PAR caused significant alterations in some biochemical and lipid peroxidation parameters and the activities/levels of drug metabolising parameters in the liver and that COL normalised some of these parameters and reduced PAR-induced tissue damage., Erciyes University [TSA-1137], This research (project code: TSA-1137) was supported by the Scientific Research Fund of Erciyes University.

WOS: 000461242900006, PubMed ID: 30906548, The present study aimed to investigate the possible association between the genetic polymorphism of the enzyme superoxide dismutase 2 (SOD2, also known as manganese-dependent SOD), Ala16Val (rs4880), and primary brain tumor risk in the Turkish population. Frequency of the SOD2 gene rs4880 polymorphism was identified in 225 Turkish individuals (120 controls and 105 patients with primary brain tumor) by polymerase chain reaction-restriction fragment length polymorphism. Subject demographics and clinical characteristics were also recorded. The findings were evaluated using logistic regression and chi(2) tests. Logistic regression analysis indicated that smoking did not increase the risk for primary brain tumor [ odds ratio (OR)= 0.77, 95% confidence interval (CI)= 0.44-1.33, chi(2)= 0.352, P= 0.860]. Similarly, there was no statistically significant difference in the family history of cancer incidence between the control subjects and the primary brain tumor patients (OR= 0.81, 95% CI= 0.39-1.71, chi(2)= 0.340, P= 0.560). There was no significant association of the histopathological type, genotype/ allele frequencies and inheritance models of tumor with the gene variants among the patients with primary brain tumor. In summary, the results of the present study indicated that the Ala16Val polymorphism of the SOD2 gene was not associated with primary brain tumor risk in the Turkish population studied., Sivas Cumhuriyet University (Sivas, Turkey) [CUBAP T-403], The current study was funded by Sivas Cumhuriyet University (Sivas, Turkey) via research grants (grant no. CUBAP T-403) provided to the project.

WOS: 000373609300023, PubMed ID: 26561326, In this study, the effects of cypermethrin (CYP), amitraz (AMT) and combined cypermethrin-amitraz (CYP-AMT) on some serum biochemical, oxidative stress and drug-metabolising parameters were investigated in male Wistar albino rats. CYP, AMT and combined CYP-AMT were administered at doses of 80 mg kg(-1) bw(-1) of CYP and 170 mg kg(-1) bw(-1) of AMT for 1 day (single dose), and at doses of 12 mg kg(-1) bw(-1) of CYP and 25 mg kg(-1) bw(-1) of AMT for 40 days by oral gavage. Oxidative stress (malondialdehyde (MDA), nitric oxide (NO), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and glucose-6-phosphate dehydrogenase (G6PD)), serum biochemical (glucose, triglyceride, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), blood urea nitrogen (BUN), creatinine, asparatate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), total protein, albumin) in blood/tissues (liver, kidney, brain, spleen and testis) and hepatic drug-metabolising (cytochrome P450 2E1 (CYP2E1), NADH-cytochrome b(5) reductase (CYPb5), NADPH-cytochrome c reductase/NADPH cytocrome P450 reductase (CYTC), glutathione S-transferase (GST), glutathione (GSH)) parameters were measured in liver samples taken on days 1 and 40. In result, it was determined that CYP, AMT and their combinations led to significant changes in the parameters investigated, and it was ascertained that long-term exposure to insecticides and the administration of insecticide combinations produced greater toxic effects in comparison with the administration of insecticides alone., Erciyes University [TSA-091132], This research (project code: TSA-091132) was supported by the Research Fund of Erciyes University.

WOS: 000405114700002, Introduction: Association between Murine double minute 2 T309G polymorphism and lung cancer risk has been investigated in several populations, but results of these studies are inconsistent. We aimed to investigate the effect of Murine double minute 2 T309G polymorphism on development of lung cancer in a Turkish population. Methods: Total 200 subjects including 100 patients and 100 controls were analyzed and used polymerase chain reaction and restriction fragment length polymorphism methods for genotyping analysis of the polymorphism. Results: We found that smokers compared with nonsmokers have approximately eight fold higher lung cancer risk [p = 0.0001, OR = 8.27 (4.02-16.9)]. Frequency of GG genotype was higher in patients than in controls, but this ratio was not significant (chi(2) = 3.5, p = 0.17). Genotype distribution of the polymorphism was not different neither patients with non-small cell lung cancer nor patients with small cell lung cancer (chi(2) = 2.89, p = 0.57). We analyzed together with demographic feature (except smoking habit), clinicopathological findings and genotype frequencies of this polymorphism, and any association with lung cancer risk was not obtained. Conclusion: No correlation between Murine double minute 2 T309G polymorphism and lung cancer risk was detected in this Turkish population.

WOS: 000405114700008, Objective: A genetic polymorphism of SOD1 A251G(rs2070424) is in the 3rd intron region of the SOD gene. The aim of this study was to determine the frequencies of the polymorphisms of the SOD1 A251G in a Turkish population, including 494 healthy individuals. Methods: The 494 Turkish individuals were genotyped for polymorphisms of SOD1 gene. The distribution of SOD1 A251G polymorphisms in this population was examined using a PCR-RFLP method. Genotype and allele frequencies were estimated by counting. Hardy-Weinberg equation between expected and observed genotype distributions was assessed using the X-2 test. Results: In the present study, the distribution of SOD1 A251G polymorphisms in a Turkish population including 494 (females: 278, 56.3% and males: 216, 43.7%) healthy individuals was examined. The mean age of the study population was 38.4 +/- 16.6 years (males, 39.8 +/- 17.1; females, 37.3 +/- 16.1). The observed genotype frequencies of SOD1 A251G were 86.2, 13.4 and 0.4% for AA, AG and GG, respectively. Conclusions: This study provides basic information about the allele and genotype frequency distributions of polymorphisms in the SOD1 A251G gene studied. These frequencies may be useful parameters as a reference for future studies on genetic basis of various diseases and cancer susceptibility.

WOS: 000391387000001, PubMed ID: 27751972, Objective: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent F-18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent F-18-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN= pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p< 0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p> 0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p> 0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion., Cumhuriyet University Scientific Research Project Unit [T-597], The work was supported by grants from Cumhuriyet University Scientific Research Project Unit (T-597).